Blueprint Medicines Corporation
Clinical trials sponsored by Blueprint Medicines Corporation, explained in plain language.
-
Promising new drug tames rare blood cancer in early trial
Disease control CompletedThis study tested a drug called avapritinib in 107 people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug targets a specific genetic change that drives the disease. Results showed that many participants experienced significant improvement or remis…
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 17, 2026 03:32 UTC
-
New drug shows promise for kids with rare cancers
Disease control CompletedThis study tested a drug called avapritinib in 29 children aged 2 to 18 with advanced solid tumors that have specific gene changes (KIT or PDGFRA). The goal was to see if the drug is safe and can shrink tumors. Since these children had no other treatment options, the study aimed …
Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New pill could ease ragweed allergy misery
Symptom relief CompletedThis study tested a new drug called BLU-808 in 21 adults with ragweed allergies. The goal was to see if it is safe and can reduce symptoms like sneezing and itchy eyes. Participants were exposed to ragweed pollen in a special chamber to measure the drug's effects.
Phase: PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated May 13, 2026 16:02 UTC
-
Healthy women help test drug interactions with elenestinib
Knowledge-focused CompletedThis study looked at how a drug called elenestinib changes the way the body processes midazolam (a sedative) and a common birth control pill. Twenty healthy adult women took these drugs with and without elenestinib, and had blood tests to measure drug levels. The goal was to gath…
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC